Lox'd in translation: Contradictions in the nomenclature surrounding common lox site mutants and their implications in experiments

Authors

Daniel Shaw[1], Luis Serrano[1,2,3], Maria Lluch-Senar[1,4*]

Affiliations

[1] Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain
[2] Universitat Pompeu Fabra (UPF), Barcelona 08002, Spain
[3] ICREA, Pg. Lluís Companys 23, Barcelona 08010, Spain
[4] Pulmobiotics SL, Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain

Keywords

Cre-Lox, Lox66, Lox71, Lox72, LoxP

Data Summary

The authors confirm all supporting data, code and protocols have been provided within the article or through supplementary data files.

Abstract

The Cre-Lox system is a highly versatile and powerful DNA recombinase mechanism, mainly used in genetic engineering to insert or remove desired DNA sequences. It is widely utilised across multiple fields of biology, with applications ranging from plants, to mammals, to microbes. A key feature of this system is its ability to allow recombination between mutant lox sites, traditionally named lox66 and lox71, to create a functionally inactive double mutant lox72 site. However, a large portion of the published literature has incorrectly annotated these mutant lox sites, which in turn can lead to difficulties in replication of methods, design of proper vectors, and confusion over the proper nomenclature. Here, we demonstrate common errors in annotations, the impacts they can have on experimental viability, and a standardised naming convention. We also show an example of how this incorrect annotation can induce toxic effects in bacteria that lack optimal DNA repair systems, exemplified by *Mycoplasma pneumoniae*.

Introduction

The Cre-Lox system was first characterised in 1981 by Nat Sternberg and Daniel Harrison (1). It is a DNA recombinase system derived from the P1 bacteriophage, and consists of two components. The first, the Cre recombinase, is a 38-kDa monomeric tyrosine recombinase. This protein acts upon a pair of 34bp lox sites (**l**ocus **o**f (**x**)crossing over), which consist of an 8-bp central spacer region flanked by two 13-bp inverted repeat regions (2,3). The central spacer unit of the lox site gives it a 'directionality', which dictates the outcome of the reaction between the Cre recombinase and DNA, as shown in Figure 1. This outcome depends on the orientation of the mutant lox sites. If they are in the same (*cis*) orientation, recombination

44 results in the circularisation of the genomic DNA between the two lox sites, and thus its
45 removal from the genome. If the lox sites are in opposite (*trans*) orientations, then the DNA
46 between them is inverted as a consequence of the recombination event.

48
49

Figure 1: Sequence and orientation of the WT loxP site, and effect of orientation on lox recombination reactions. (A) Sequence
of the loxP site, with the 13-bp inverted repeats in lighter blue, and the central spacer region in darker blue. The arrow indicates
the directionality of the lox site. (B) Action of the Cre recombinase (grey) on two lox sites in *cis* orientation. DNA between the
two sites is excised and circularised, leaving 1 lox site in the genome and 1 lox site on the circular DNA. (C) Action of the Cre
recombinase when lox sites are in *trans*. DNA between the two sites is inverted.

For the sake of brevity, a full review into the history of the Cre recombinase and its reaction
kinetics are outside the scope of this paper, and have been discussed at detail by other
authors (4–7). Instead, here we will focus on one aspect of the Cre-Lox system; its ability to
utilise mutant lox sites, and how these sites interact.

The two most widely used lox mutations are the lox66 and lox71 sites, which were first
described in 1995 (8). These lox mutants contain alterations to their initial or terminal 5 base
pairs, with the lox66 having the first 5 bases changed, and lox71 having the last 5 bases
changed (in regard to the canonical loxP), shown below in Table 1:

Table 1: The sequence of the canonical loxP site and its mutants, with directionality of the lox site from left to right.

Lox site	Sequence (5' to 3' leading strand)

LoxP	ATAACTTCGTATA GCATACAT TATACGAAGTTAT
Lox66	ATAACTTCGTATA GCATACAT TATACGAAcggta
Lox71	taccgTTCGTATA GCATACAT TATACGAAGTTAT
Lox72	taccgTTCGTATA GCATACAT TATACGAAcggta

The Cre recombinase exists as a monomer, however during recombination it forms a
tetramer, with one molecule attached to each flanking region of the two lox sites (5). As
shown in Figure 2 below, modified from the review of the Cre recombinase by Gregory Van
Duyne (5), the Cre complex manoeuvres the two DNA strands so that the lox sites are
brought together. The arrows indicate the directionality of the lox sites, and as the complex is
formed they face in opposite directions. The lagging strand from both DNA molecules is then
cleaved, and annealed to the other DNA molecule via a Holliday junction-forming reaction.
The same then occurs for the other strand, resulting in the left element of the first lox site
becoming joined to the right element of the second, and vice versa.

78
Figure 2: Modified from Van Duyne (5). Shows the reaction pathway of the Cre recombinase complex on two loxP sites, with
the stands of each DNA molecule shown in separate colours, with the top strands in black and blue, and the bottom strands in
red and green. The direction of the lox sites is indicated by the coloured arrows. (A) The Cre recombinase molecules bind to
each homology arm of each lox site (B) The Cre-lox complex is formed, with the four Cre molecules bringing the DNA together
so the two lox sites run antiparallel to each other. (C) Cleavage of the bottom strands by Tyr324 in the Cre subunits. (D)
Formation of 3'-phosphotyrosine linkages between the bottom strands leads to the creation of a 4-way Holliday junction
between the two DNA molecules. (E) Cleavage of the top strands allows for strand exchange between the two DNA molecules.
(F) Top strands of both molecules are ligated together. (G) Formation of the two new lox sites. (H) New lox sites contain the 5'
homology arm of the first lox site, with the 3' homology arm of the second, and vice versa.

As both lox sites in the diagram are identical, they do not change their sequence via
recombination, as every flanking region is identical. However, as each new lox site
generated is a combination of both previous sites, when two different mutant lox sites are
incorporated, a double mutant is always created. This is due to the Cre recombinase
complex to manoeuvre the DNA strands into an antiparallel formation ensures that one 'side'
of the reaction will always contain both mutant flanking regions, and thus will combine
together (9).
96

97 The Cre recombinase can recognise the single mutant lox66 and lox71 with the same affinity
98 as the loxP, however the double mutant lox72 shows a marked decrease in affinity for the
99 Cre (8), making the site functionally silent. This lack of affinity for the lox72 site allows for
100 multiple lox reactions to occur in a genome in series, without affecting or cross-reacting with
101 each other (10–12).
102

In this paper, we show a comprehensive analysis of the literature associated with lox66 and
lox71 sites, with examples of the common errors that have occurred in the nomenclature and
a standardised naming convention to help resolve these remaining ambiguities. We also
highlight the dangers of such errors, demonstrating that the presence of a single active lox
site within a bacterial genome can initiate a lethal phenotype, on par with a double strand
break in the DNA. We use *Mycoplasma pneumoniae* as a model organism, and demonstrate
that the lethality associated with the Cre acting on a single lox is analogous to a double
stranded break generated by the meganuclease *I-SceI,* which we also report to be active in
M. pneumoniae for the first time.
112

113 With the demonstration that there occurs mis-annotation of both the mutant arms of the lox
114 sites, and also their directionality, we demonstrate the potentially destructive consequences
115 of when these errors are compounded. This occurred within our own lab, and we hope that
116 this publication may avert the same issues in future experiments, and potentially explain why
117 some previous experiments may have failed.
118

Methods

Literature review of lox site nomenclature

A literature review aiming to capture as many of the papers describing the interactions
between lox66 and lox71 sites was performed (See Figure 3). Many papers were present via
multiple search terms, so replicates were removed. The papers were then queried for their
relevance to the topic, specifically if they included the use of the lox66 or lox71 site within
their methodology or discussion. Those papers that used the sites in a material way were
included, and all others discarded.
128

The remaining 47 papers were then judged for their accuracy in regard to the lox site
nomenclature. The benchmark used for accuracy was the nomenclature described in the
original paper by Albert et al., (8). Papers which provided the sequence of the lox sites they
used were filtered into either the "Correct" or "Incorrect" category, depending on if the
nomenclature they used was in concordance with Albert et al. All papers that did not show
the sequence of the lox sites were placed within the "Unclear" category.

Strains and culture conditions

Wild-type *Mycoplasma pneumoniae* strain M129 (ATTC 29342, subtype 1, broth passage
no. 35) was used. Cells were cultured in 75cm^3 tissue culture flasks at 37°C in standard
Hayflick media, as described by Hayflick (13) and Yus et al., (14), supplemented with 100
µg/ml ampicillin, 2 µg/ml tetracycline, 20 µg/ml chloramphenicol, 3.3µg/ml puromycin and
200 µg/ml gentamicin as appropriate. Hayflick agar plates were created by supplementing
the Hayflick with 1% Bacto Agar (BD, Cat. No. 214010) pre autoclave.

NEB 5-alpha Competent *E. coli* cells (New England Biolabs, Catalogue number C2987H)
were used for plasmid amplification and cloning. They were grown at 37°C in Lysogeny
Broth (LB) at 200RPM or static on LB agar plates, supplemented with 100µg/ml ampicillin.

Plasmid DNA

147 All plasmids were generated using the Gibson isothermal assembly method (15). DNA was
148 isolated from NEB 5-alpha Competent *E. coli* cells, and individual clones were selected for
149 using LB + ampicillin plates (100 µg/ml). Correct ligation was confirmed via Sanger
150 sequencing (Eurofins Genomics). A list of all plasmids, and primers used in their generation
151 and sequencing can be found in Suppl. Tables 1 & 2.

Single lox site lethality

WT M129 cells were transformed according to the protocol outlined by Hedreyda et al (16).
Cells were grown to mid-log phase, identified by the Hayflick media changing from red to
orange. The media was decanted and the flask was washed 3x with 10ml chilled
electroporation buffer (EB: 8mM HEPES, 272nM sucrose, pH 7.4). Cells were scraped into
500µl chilled EB and homogenised via 10x passages through a 25-gauge syringe needle.
Aliquots of 50µl of the homogenised cells were mixed with a pre-chilled 30µl EB solution
containing the 1pMole of pMTn_Lox66_Sce_Cm plasmid DNA. Samples were then kept on
ice for 15 mins. Electroporation was done using a Bio-Rad Gene Pulser set to 1250 V, 25 µF
and 100Ω. After electroporation, cells were incubated on ice for 15 mins, then recovered into
a total of 500µl Hayflick media and incubated at 37°C for 4 hours. 125µl of transformed cells
were then inoculated into T75 culture flasks containing 20ml Hayflick and supplemented with
20 µg/ml chloramphenicol.

The transformed cells were grown to mid-log phase, then isolated. To ensure the recovery of
planktonic cells, the media was transferred to a 50ml Falcon tube. The flask was then
scraped into 500µl Hayflick, which was added to the Falcon tube with the media. The sample
was centrifuged at 10,000RPM at 4°C for 10 mins to pellet the cells. The supernatant was
discarded and the cells re-suspended in 500µl chilled EB. A fresh batch of WT M129 cells
was also prepared. The cells were homogenised via 10x passages through a 25-gauge
syringe needle. Aliquots of 50µl of the homogenised cells from both conditions were
incubated with a pre-chilled 30µl EB solution containing the 1pMole of either the
pBSK_p438_Sce_Puro, pBSK_p438_Cre_Puro or pBSK_p438_Puro plasmid, and
transformed using the previously described settings. Cells were recovered in the same
manner, and 125µl were inoculated into a T75 flask containing 20ml Hayflick media
supplemented with XX µg/ml puromycin, and incubated at 37°C for 5 days.

After the incubation period, cells were isolated via the centrifugation protocol specified
above. The pellets were dissolved in 500µl of fresh Hayflick media, and serial diluted. 10µl
spots of each dilution were then plated on Hayflick agar plates, and incubated at 37°C for 1
week before being counted.

Results

182
183 Figure 3: Flowchart describing the generation of the literature review. The square boxes show the data acquisition and filtering
184 steps in order of occurrence, and the diamonds show the number of papers being considered after each step.. The final 47
185 chosen papers were analysed for their use of lox nomenclature, and classified appropriately, as described in the text above.
186

A large number of papers were omitted from the initial pool of papers, are two main reasons
for this. First, all of the papers found with the searches for specific lox sites were also found
in the "Mutant lox site" search, indicating that the remaining papers were more tangentially
related to the topic. While almost all papers from the first three searches were relevant, very
few papers from the final search were relevant that had not already been accounted for.
Second, the "Mutant lox site" search returned a large number of papers that were not
germane to the topic of this review. They generally fit into three further categories; i) Papers
involving mutant lox sites that were not lox66 or lox71. ii) Papers describing mutants created
by protocols using other lox sites, typically loxP or loxM variants. iii) Papers involving LOX
genes, typically from *Pseudomonas aeruginosa.*

Table 2: Classification of the 47 relevant papers

Correct papers	Incorrect papers	Unclear papers
References (8,10,12,17–34)	References (35–42)	References 36–53

200 In total, we found that 8/47 (17%) of papers surveyed had incorrectly labelled their lox sites.
201 Of these, 7 of the 8 papers (35,36,38–42) had simply mislabelled the lox sites, ascribing the
202 lox66 name to the canonical lox71, and *vice versa*. The remaining paper (37) correctly
203 annotated the lox sites, but implied the directionality of the lox site was in the opposite
204 direction to which it was written.
205

The strict criteria employed in classifying papers as either correct or incorrect meant that a
large number of relevant papers did not fit into either the correct or incorrect category. The
main reason for this was that they did not explicitly state the sequences of the lox sites that
they used. Looking at the figures and methodologies, all of them seem to follow convention
and appear to use the lox sites correctly. Furthermore, almost every paper references either
Albert et al., (8), Leibig et al., (24) or Araki et al., (17) when discussing the addition of lox
sites into a construct. All three of these papers show correct annotations for the lox sites that
they use.
214

215 However, just having the correct reference is not enough to guarantee that the lox site is
216 correct. In Table 1 of Missirlis et al., (40), they show incorrect sequences for lox66 & lox71
217 while referencing Albert et al. (8) and Araki et al. (17) for both. Therefore, it seemed
218 reasonable to separate the clear-cut cases from the ambiguous ones, as to create a 'gold
219 standard' of reporting in relation to lox site nomenclature.
220

221 <u>Lethality conferred by single lox sites</u>
222

We were interested in examining the potential effects of mis-labelling the lox sites on
experimental viability. If one or more lox sites are not correct, or are not internally consistent,
then there is the possibility of an active lox site being formed instead of a lox72, likely due to
an inversion between the lox sites taking place instead of a deletion. The most damaging
scenario would be both the mis-annotation of the lox sites, and their directionality. This
occurred within our own laboratory, and resulted in months of troubleshooting before its
resolution.
230

231 This is not encountered in the literature, though this may be via experiments failing and not
232 generating publishable results. As such, we decided to test the effect of a single lox site
233 being present in the genome of a bacteria with the Cre recombinase being expressed, to
234 validate if this annotation error had caused the failure of the experiment.
235

Using *M. pneumoniae* as a model system, we transformed the cells with a transposon
containing a single lox66 site, along with an *I-SceI* meganuclease recognition sequence. The
I-SceI meganuclease induces a double stranded break in the genome, which is lethal to *M.*
pneumoniae due to its limited DNA repair mechanisms (60), and provides a good baseline
control for lethality. While the usage of the *I-SceI* meganuclease has not been previously
demonstrated in *M. pneumoniae*, it has been expressed in other mollicute species, such as
Spiroplasma citri (61), where it was also used to induce a lethal phenotype.
243

244 The *M. pneumoniae* cells were transformed with a transposon containing the *I-SceI*
245 meganuclease recognition site, a lox66 site, and a chloramphenicol resistance gene. They

246 were then transformed with a suicide vector containing either a Cre recombinase gene, the *I-*
247 *SceI* meganuclease, or an empty control, alongside the WT cells.
248

249
250 Figure 4: Effect of incorporating incorrect lox sites on experimental viability. CFU (colony forming unit) count after transforming
251 a *M. pneumoniae* M129 containing a single lox site and a *M. pneumoniae* M129 WT strain with different suicide vectors
252 containing either the Cre recombinase, *I-SceI* meganuclease or an empty control. Error bars indicate 2 standard deviations
253 from the mean. Data from WT M129 cells shown in green, and M129 with a single lox site integrated into the genome in
254 orange.
255

As shown in Figure 4, there is a clear lethal phenotype exhibited by the action of the Cre on
cell lines with a single lox site present, as after 5 days of incubation with the relevant
plasmids, we demonstrate a 3-fold reduction in cell viability measured by CFU, which is near
identical to the lethality induced by the double stranded break enacted by the *I-SceI*. We
therefore demonstrate that both the action of the Cre on a single lox site can cause cell
death in *M. pneumoniae*, and also that the *I-SceI* meganuclease can be expressed and
active within the system.
263

<u>Discussion</u>

We have shown that there are a large number of errors found within the relevant lox
literature. The main cause of these errors potentially stems from the reporting of the original
sequences in the paper by Albert et al (8). In Figure 3 of their paper, the sequences are
shown of the relevant lox sites. Here, the directionality of the lox is facing right to left.
However, many of the papers with an error depict the lox site running left to right. In
essence, they have switched the directionality of the central spacer region, without also
changing which flanking arm contains a deletion.
272

Figure 5: Common examples of lox mis-annotation, showing correct and incorrect examples for each directionality. All mutant regions are underlined. (A) Taken from Albert et al. (8). Shows the original description of the lox66, lox71 & lox72 in relation to the loxP. (B) Sequences taken from Leibig et al. (24). (C) Sequences taken from Weng et al. (42). (D) Sequences taken from Guan et al. (39).

In the original paper, Albert et al. (8) describes the sites as both lox66 & lox71, but also as "a site with a mutation in the [left element] (LE mutant site) and a site with a mutation in the [right element] (RE mutant site)". However, the paper does not openly state which is which. In turn the reader is forced to interpret this as either left or right with regard to the directionality of the lox site, or 5' to 3' of the given sequence. Therefore, while the diagram of the mutant lox sites is clearly demarcated, the addition of the poorly characterized LE and RE annotations is ambiguous, and may have led to the errors described below.

It is worth emphasising at this point that these errors do not affect the scientific validity of the papers they are found in, as the constructs each author describes will create inactive lox sites. It is simply that the annotations the authors attribute the lox sites they use are incorrect. In the papers found with errors in lox site annotations, they fall into two distinct categories; i) miss-annotation of the lox site name, and ii) miss-annotation of the direction of the lox site.

A good example of the lox sites being simply miss-annotated is shown by Carter & Delneri (35). In their paper, they refer to the lox sites as Left Element and Right Element mutants to try and avoid confusion. Their premise is to flank genes for deletion with mutant lox sites, induce a deletion and create a silent lox72 site, as shown in Figure 1 of their paper, reproduced below:

ATAACTTCGTATA ATGTATGC TATACGAAGTTAT

TACCGTTCGTATA ATGTATGC TATACGAA**CGGTA**

Figure 6: Modified version of Figure 1 from Carter and Delneri (35) showing the schematic of their Cre-lox deletion protocol, where their gene of interest (G.O.I) is flanked by different lox sites. (A) The action of the Cre on the DNA causes a deletion between the two LoxP sites, leaving a LoxP in the genome. (B) The action of the Cre on the DNA leaves an inactive double mutant lox site.

As shown in Figure 6, the lox sites are inserted running left to right, as indicated by the arrows, with the 5' or left element of the first lox mutated and the 3' right element of the second lox mutated. This will give the mutant lox site shown in the figure. However, when looking at the table of oligos provided in Table 1 of the paper, reproduced below, the oligos used to create the lox sites do not match with their role in Figure 6.

Table 3: Modification of Table 1 from Carter and Delneri (35). Annotations to the sequences added for clarity, with spacer unit in **bold**,and the mutant regions underlined.

Primer	Sequence (5' to 3')	Note
LE_F	GATCCGGGCCCTACCGTTCGTATA **ATGTATGC** TATACGAAGTTATTCTAGAA	Contains lox71 site
LE_R	GATCTTCTAGAATAACTTCGTATA **GCATACAT** TATACGAACGGTAGGGCCCG	Contains lox71 site
RE_F	CGATACCTGGAAGTCGACATAACTTCGTATA **ATGTATGC** TATACGAACGGTAGATATCACGTTGCAA	Contains lox66 site
RE_R	CTAGTTGCAACGTGATATCTACCGTTCGTATA **GCATACAT** TATACGAAGTTATGTCGACTTCCAGGTAT	Contains lox66 site

The "Note" column shows the authors' annotations for the lox sites. However, both are incorrect, as when the lox site is written in a left to right directionality, the left arm mutant is the lox66, not the lox71 (24). The lox sites are still in the correct orientation, and the correct arms are mutated in each instance. Therefore, while the reaction schematic provided by Carter & Delneri is correct, and will give rise to a mutant lox72 site, the original lox sites are simply miss-labelled.

An example of attributing the wrong direction to the lox site can be found with Weng et al.
(42). Figure 7 is an adaptation of Figure 1 from their paper. It shows a self-existing construct
flanked by mutant lox sites, with their sequences shown below. The figure shows the lox
sites in a left to right orientation, however the sequences of the lox sites shown below it are
in a right to left direction. Therefore, the lox66 and lox71 annotations are incorrect. However,
this will not affect the validity of the experimental design, as a lox72 will still be formed upon
the action of the Cre. The lox66 site described as being in a left to right orientation is in truth
a lox71 site in right to left orientation, with the opposite being true for the lox71 site. Simply,
the arrows in the figure should be shown in the opposite direction, with the mutant regions of
the lox sites still on the 5' and 3' arms respectively.

333
334 Figure 7: Simplified experimental schematic, modified from Figure 1 of Weng et al (42). (A) Simplification of the original Figure
335 1 from Weng et al., (42), showing the directionality and labels attributed to the lox sites used, and their specific sequences. (B)
336 Our modified figure, showing the true annotations and orientations of the construct, with changes in red.
337

338 The use of incorrect lox sites has the potential to severely undermine experimental design. If
339 the identity of a lox site is incorrectly determined, then a deletion that aimed to create an
340 inactive lox72 could instead create an active loxP. We have shown that the action of the cre
341 upon a single active lox site within the genome can have severe consequences for the cell,
342 showing a lethal phenotype in *M. pneumoniae.*
343

344 The cause of this lethality is currently unknown, however we currently have two main
345 hypotheses. The first, is that the Cre attempts the reaction despite the second lox site not
346 being present. The cleaved leading strand then has no receptor, and thus a nick is formed. If
347 the lagging strand is also cut, then this will form a double stranded break in the DNA, which
348 is highly lethal in most bacteria (62).
349

350 The second hypothesis is that the Cre becomes irreversibly bound to the DNA, as the
351 reaction stalls due to lack of components. This may leave the Cre bound to the DNA during
352 the strand cleavage reactions, and thus not only create nicks and potential double strand
353 breaks, but also become a hindrance to DNA transcription, translation and replication
354 machinery.
355

Regardless of the cause, it is apparent that this action has applications in engineering
purposes, as either a kill switch mechanism or selection against cells that have undergone
unwanted DNA inversions. This was demonstrated by Shaw et al., (in preparation) as a
highly effective counter-selection system to remove unwanted inversions when lox sites
were added randomly to the genome of *M. pneumoniae*, leaving only cells that had
undergone a deletion and produced an inactive lox72 site, as cells that contained inversions
which produced active lox sites were killed.
363

364 <u>Conclusions</u>
365

Of the 21 articles that unambiguously showed the correct lox site annotations, 18/21 used
the same lox orientation as the original paper by Albert et al. (8), with the lox directionality
reading from right to left (8,12,17–23,25–34). In contrast, 5 of the 8 papers with mis-labelled
lox sites portray them from left to right (35,37,39–41). It seems apparent that there is
potential for the mis-annotation of these sequences, and that this could stem from incorrectly
assuming either lox site directionality, or by accidentally attributing the wrong name to the
correct site.
373

While the cases identified here are benign, with miss-annotations not affecting the outcomes
of the experiments, the prevalence of these errors is worrying. Attempts at replication, or
researches using these maps or constructs as the basis for their own experiments may
inadvertently create incompatible designs of vectors, and thus cause delays and errors in
future experiments. We have demonstrated that the action of the Cre on a single lox site can
have a lethal effect, and therefore the authors believe that special care should be taken to
properly attribute the correct names to lox sites.
381

As such, it seems prudent to recommend that researchers continue using the annotations
provided by Albert et al (8), repeated below, as this is the form taken by the majority of the
correct cases, and unused by the majority of the incorrect ones. We also recommend the
avoidance of the left or right element notation, as it is too ambiguous and dependent on
orientation. If the lox site is written from right to left, then the LE mutant would be the lox71,
however if the lox site is written left to right, then the LE becomes lox66. Therefore in the aim
of standardisation, we recommend following the original notation and designing lox sites
from right to left whenever possible:
390

391 Lox66:   5' - ATAACTTCGTATA GCATACAT TATACGAAcggta - 3'
392   ←
393 Lox71:   5' - taccgTTCGTATA   GCATACAT TATACGAAGTTAT - 3'
394

395 By adopting a more standardised nomenclature, hopefully the internal reproducibility and
396 accuracy of the reporting of lox sites, and errors or confusion caused by the usage of
397 incorrect sites can be minimised.
398
399 <u>Supplementary Tables</u>
400 Table S1: List of all plasmids used in this study.

Name	Description	Reference
pMTnCat	pMTn4001 containing a chloramphenicol resistance gene under the control of the 22 bp pM438 promoter from *Mycoplasma genitalium*.	(63)
pBSK_Cre_Sce_Puro	Modified pBSKII+ vector, containing the Cre recombinase, *I-SceI* meganuclease and puromycin resistance under the control of the pM438 promoter.	This study
pMTn_Lox66_Sce_Cm	Transposon derived from the pMTnCm plasmid, containing a lox66 site, *I-SceI* meganuclease recognition site and chloramphenicol resistance marker. Utilised the *Tn4001* transposase. The pMTnCat vector was amplified by oligos 1 & 2, creating a 4992bp band, which was self annealed.	This study
pBSK_p438_Cre_Puro	Modified pBSK_Cre_Sce_Puro vector, containing just the Cre recombinase and puromycin resistance marker under the control of the pM438 promoter. The pBSK_Cre_Sce_Puro vector was amplified with oligos 3 & 4, creating a 4646bp band, which was self annealed.	This study
pBSK_p438_Sce_Puro	Modified pBSK_Cre_Sce_Puro vector, containing just the *I-SceI* meganuclease and puromycin resistance marker under the control of the pM438 promoter. The pBSK_Cre_Sce_Puro vector was amplified with oligos 5 & 6, creating a 4285bp band, which was self annealed.	This study
pBSK_p438_Puro	Modified pBSK_Cre_Sce_Puro vector, containing just a puromycin resistance marker under the control of the pM438 promoter. The pBSK_Cre_Sce_Puro vector was amplified with oligos 7 & 6, creating a 4285bp band, which was self annealed.	This study

401
402

403   Table S2: List of oligos used in this study

Name	Sequence (5' to 3')
1	TACCGTTCGTATAATGTATGCTATACGAAGTTATTAGGGATAACAGGGTAATTAGTATTTAGAATTAATAAAGTATG
2	ATTACCCTGTTATCCCTAATAACTTCGTATAGCATACATTATACGAACGGTACGATATCAAGCTTATCGATACC
3	CCTGAAATAACGAATTCCTGC

4	CAGGAATTCGTTATTTCAGGCTAGAATTCGATCTAATCGCC
5	ACGGTATCGATAAGCTTGATAATTCTAGTATTTAGAATTAATAAAGTATGC
6	ATCAAGCTTATCGATACCG
7	ACGGTATCGATAAGCTTGATATAACGAATTCCTGCAGGG

Author Contributions

Daniel Shaw:

Conceptualization
Data curation
Formal analysis
Investigation
Methodology
Validation
Visualization
Writing – original draft
Writing – review & editing

Luis Serrano:

Conceptualization
Funding acquisition
Resources
Supervision
Writing – review & editing

Maria Lluch-Senar:

Conceptualization
Supervision
Writing – review & editing

Conflicts of Interest

427 The authors declare that there are no conflicts of interest.

Funding information

This project has received funding from the European Union's Horizon 2020 research and
innovation programme under grant agreement 634942 (MycoSynVac) and was also financed
by the European Research Council (ERC) under the European Union's Horizon 2020
research and innovation programme, under grant agreement 670216 (MYCOCHASSIS). We
also acknowledge support of the Spanish Ministry of Economy, Industry and
Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa
and the CERCA Programme/Generalitat de Catalunya.

References

1. Sternberg N, Hamilton D. Bacteriophage P1 site-specific recombination. I.
Recombination between loxP sites. J Mol Biol. 1981 Aug 25;150(4):467–86.

2. Sternberg N, Hamilton D, Austin S, Yarmolinsky M, Hoess R. Site-specific
recombination and its role in the life cycle of bacteriophage P1. Cold Spring Harb Symp
Quant Biol. 1981;45 Pt 1:297–309.
3. Ghosh K, Van Duyne GD. Cre-loxP biochemistry. Methods San Diego Calif. 2002
Nov;28(3):374–83.
4. Yarmolinsky M, Hoess R. The Legacy of Nat Sternberg: The Genesis of Cre-lox
Technology. Annu Rev Virol. 2015 Nov;2(1):25–40.
5. Van Duyne GD. Cre Recombinase. Microbiol Spectr. 2015 Feb;3(1):MDNA3-0014–
2014.
6. Song AJ, Palmiter RD. Detecting and Avoiding Problems When Using the Cre/lox
System. Trends Genet TIG. 2018 May;34(5):333–40.
7. Sauer B. Cre/lox: one more step in the taming of the genome. Endocrine. 2002
Dec;19(3):221–8.
8. Albert H, Dale EC, Lee E, Ow DW. Site-specific integration of DNA into wild-type and
mutant lox sites placed in the plant genome. Plant J Cell Mol Biol. 1995 Apr;7(4):649–
59.
9. Gelato KA, Martin SS, Wong S, Baldwin EP. Multiple levels of affinity-dependent DNA
discrimination in Cre-LoxP recombination. Biochemistry. 2006 Oct 10;45(40):12216–26.
10. Lambert JM, Bongers RS, Kleerebezem M. Cre-lox-Based System for Multiple Gene
Deletions and Selectable-Marker Removal in Lactobacillus plantarum. Appl Environ
Microbiol. 2007 Feb;73(4):1126–35.
11. Zhang S, Ban A, Ebara N, Mizutani O, Tanaka M, Shintani T, et al. Self-excising
Cre/mutant lox marker recycling system for multiple gene integrations and consecutive
gene deletions in Aspergillus oryzae. J Biosci Bioeng. 2017 Apr 1;123(4):403–11.
12. Suzuki N, Nonaka H, Tsuge Y, Inui M, Yukawa H. New multiple-deletion method for the
Corynebacterium glutamicum genome, using a mutant lox sequence. Appl Environ
Microbiol. 2005 Dec;71(12):8472–80.
13. Hayflick L. Tissue cultures and mycoplasmas. Tex Rep Biol Med. 1965 Jun;23:Suppl
1:285+.
14. Yus E, Maier T, Michalodimitrakis K, Noort V van, Yamada T, Chen W-H, et al. Impact
of Genome Reduction on Bacterial Metabolism and Its Regulation. Science. 2009 Nov
27;326(5957):1263–8.
15. Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO. Enzymatic
assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009
May;6(5):343–5.
16. Hedreyda CT, Lee KK, Krause DC. Transformation of Mycoplasma pneumoniae with
Tn4001 by electroporation. Plasmid. 1993 Sep;30(2):170–5.
17. Araki K, Araki M, Yamamura K. Targeted integration of DNA using mutant lox sites in
embryonic stem cells. Nucleic Acids Res. 1997 Feb 15;25(4):868–72.
18. Araki K, Araki M, Yamamura K. Site-directed integration of the cre gene mediated by
Cre recombinase using a combination of mutant lox sites. Nucleic Acids Res. 2002 Oct
1;30(19):e103.
19. Araki K, Okada Y, Araki M, Yamamura K. Comparative analysis of right element mutant
lox sites on recombination efficiency in embryonic stem cells. BMC Biotechnol. 2010
Mar 31;10:29.
20. Bertram R, Kolb M, Hillen W. In vivo activation of tetracycline repressor by Cre/lox-
mediated gene assembly. J Mol Microbiol Biotechnol. 2009;17(3):136–45.
21. Jiang Y, Gao X, Xu K, Wang J, Huang H, Shi C, et al. A Novel Cre Recombinase-
Mediated In Vivo Minicircle DNA (CRIM) Vaccine Provides Partial Protection against
Newcastle Disease Virus. Appl Environ Microbiol [Internet]. 2019 Jul 1 [cited 2020 Mar
19];85(14). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606863/

22. Koussis K, Withers-Martinez C, Baker DA, Blackman MJ. Simultaneous multiple allelic
replacement in the malaria parasite enables dissection of PKG function. Life Sci
Alliance. 2020 Apr;3(4).
23. Langer SJ, Ghafoori AP, Byrd M, Leinwand L. A genetic screen identifies novel non-
compatible loxP sites. Nucleic Acids Res. 2002 Jul 15;30(14):3067–77.
24. Leibig M, Krismer B, Kolb M, Friede A, Götz F, Bertram R. Marker Removal in
Staphylococci via Cre Recombinase and Different lox Sites. Appl Environ Microbiol.
2008 Mar 1;74(5):1316–23.
25. Liu W, Wang Y, Qin Y, Wang Y, Zhu Z. Site-Directed Gene Integration in Transgenic
Zebrafish Mediated by Cre Recombinase Using a Combination of Mutant Lox Sites.
Mar Biotechnol. 2007 Aug 1;9(4):420–8.
26. Oberdoerffer P, Otipoby KL, Maruyama M, Rajewsky K. Unidirectional Cre-mediated
genetic inversion in mice using the mutant loxP pair lox66/lox71. Nucleic Acids Res.
2003 Nov 15;31(22):e140.
27. Pan R, Zhang J, Shen W-L, Tao Z-Q, Li S-P, Yan X. Sequential deletion of Pichia
pastoris genes by a self-excisable cassette. FEMS Yeast Res. 2011 May;11(3):292–8.
28. Petersen KV, Martinussen J, Jensen PR, Solem C. Repetitive, Marker-Free, Site-
Specific Integration as a Novel Tool for Multiple Chromosomal Integration of DNA. Appl
Environ Microbiol. 2013 Jun;79(12):3563–9.
29. Suzuki N, Inui M, Yukawa H. Site-directed integration system using a combination of
mutant lox sites for Corynebacterium glutamicum. Appl Microbiol Biotechnol. 2007
Dec;77(4):871–8.
30. Tomimoto K, Yamakawa M, Tanaka H. Construction of a long hairpin RNA expression
library using Cre recombinase. J Biotechnol. 2012 Aug 31;160(3–4):129–39.
31. Wang Y, Weng J, Waseem R, Yin X, Zhang R, Shen Q. Bacillus subtilis genome
editing using ssDNA with short homology regions. Nucleic Acids Res. 2012
Jul;40(12):e91.
32. Wu L, Wu H, Chen L, Lin L, Borriss R, Gao X. Bacilysin overproduction in Bacillus
amyloliquefaciens FZB42 markerless derivative strains FZBREP and FZBSPA
enhances antibacterial activity. Appl Microbiol Biotechnol. 2015 May 1;99(10):4255–63.
33. Yan X, Yu H-J, Hong Q, Li S-P. Cre/lox System and PCR-Based Genome Engineering
in Bacillus subtilis. Appl Environ Microbiol. 2008 Sep;74(17):5556–62.
34. Zhang Z, Lutz B. Cre recombinase-mediated inversion using lox66 and lox71: method
to introduce conditional point mutations into the CREB-binding protein. Nucleic Acids
Res. 2002 Sep 1;30(17):e90.
35. Carter Z, Delneri D. New generation of loxP-mutated deletion cassettes for the genetic
manipulation of yeast natural isolates. Yeast Chichester Engl. 2010 Sep;27(9):765–75.
36. Cerisy T, Rostain W, Chhun A, Boutard M, Salanoubat M, Tolonen AC. A Targetron-
Recombinase System for Large-Scale Genome Engineering of Clostridia. mSphere
[Internet]. 2019 Dec 11 [cited 2020 Mar 19];4(6). Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908422/
37. Chatterjee PK, Shakes LA, Stennett N, Richardson VL, Malcolm TL, Harewood KR.
Replacing the wild type loxP site in BACs from the public domain with lox66 using a
lox66 transposon. BMC Res Notes. 2010 Feb 19;3:38.
38. Erler A, Maresca M, Fu J, Stewart AF. Recombineering reagents for improved inducible
expression and selection marker re-use in Schizosaccharomyces pombe. Yeast.
2006;23(11):813–23.
39. Guan Z-B, Wang K-Q, Shui Y, Liao X-R. Establishment of a markerless multiple-gene
deletion method based on Cre/loxP mutant system for Bacillus pumilus. J Basic
Microbiol. 2017 Dec;57(12):1065–8.

40.   Missirlis PI, Smailus DE, Holt RA. A high-throughput screen identifying sequence and
promiscuity characteristics of the loxP spacer region in Cre-mediated recombination.
BMC Genomics. 2006 Apr 4;7:73.

41.   Parrish M, Unruh J, Krumlauf R. BAC Modification through Serial or Simultaneous Use
of CRE/Lox Technology. J Biomed Biotechnol [Internet]. 2011 [cited 2020 Apr 2];2011.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010708/

42.   Weng L, Biswas I, Morrison DA. A Self-deleting Cre-lox-ermAM Cassette, CHESHIRE,
for marker-less gene deletion in Streptococcus pneumoniae. J Microbiol Methods. 2009
Dec;79(3):353.

43.   Xin Y, Guo T, Mu Y, Kong J. A Single-Plasmid Genome Editing System for Metabolic
Engineering of Lactobacillus casei. Front Microbiol. 2018;9:3024.

44.   Kimura Y, Ding B, Imai N, Nolan DJ, Butler JM, Rafii S. c-Kit-Mediated Functional
Positioning of Stem Cells to Their Niches Is Essential for Maintenance and
Regeneration of Adult Hematopoiesis. PLoS ONE [Internet]. 2011 Oct 26 [cited 2020
Apr 1];6(10). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202594/

45.   Taniwaki T, Haruna K, Nakamura H, Sekimoto T, Oike Y, Imaizumi T, et al.
Characterization of an exchangeable gene trap using pU-17 carrying a stop codon-
βgeo cassette. Dev Growth Differ. 2005;47(3):163–72.

46.   Döhlemann J, Brennecke M, Becker A. Cloning-free genome engineering in
Sinorhizobium meliloti advances applications of Cre/loxP site-specific recombination. J
Biotechnol. 2016 Sep 10;233:160–70.

47.   Xin Y, Guo T, Mu Y, Kong J. Coupling the recombineering to Cre-lox system enables
simplified large-scale genome deletion in Lactobacillus casei. Microb Cell Factories.
2018 Feb 12;17(1):21.

48.   Berzin V, Kiriukhin M, Tyurin M. Cre-lox66/lox71-based elimination of
phosphotransacetylase or acetaldehyde dehydrogenase shifted carbon flux in acetogen
rendering selective overproduction of ethanol or acetate. Appl Biochem Biotechnol.
2012 Nov;168(6):1384–93.

49.   Togawa Y, Nunoshiba T, Hiratsu K. Cre/lox-based multiple markerless gene disruption
in the genome of the extreme thermophile Thermus thermophilus. Mol Genet
Genomics. 2018 Feb 1;293(1):277–91.

50.   Kim JM, Lee KH, Lee SY. Development of a markerless gene knock-out system for
Mannheimia succiniciproducens using a temperature-sensitive plasmid. FEMS
Microbiol Lett. 2008 Jan;278(1):78–85.

51.   Li Z, Zhao G, Shen J, Araki K, Haruna K, Inoue S, et al. Enhanced expression of
human cDNA by phosphoglycerate kinase promoter-puromycin cassette in the mouse
transthyretin locus. Transgenic Res. 2011 Feb;20(1):191–200.

52.   Kiriukhin M, Tyurin M. Expression of amplified synthetic ethanol pathway integrated
using Tn7-tool and powered at the expense of eliminated pta, ack, spo0A and spo0J
during continuous syngas or CO_2 /H_2 blend fermentation. J Appl Microbiol. 2013
Apr;114(4):1033–45.

53.   Zhao G, Li Z, Araki K, Haruna K, Yamaguchi K, Araki M, et al. Inconsistency between
hepatic expression and serum concentration of transthyretin in mice humanized at the
transthyretin locus. Genes Cells. 2008;13(12):1257–68.

54.   Liu X-B, Liu M, Tao X-Y, Zhang Z-X, Wang F-Q, Wei D-Z. Metabolic engineering of
Pichia pastoris for the production of dammarenediol-II. J Biotechnol. 2015 Dec
20;216:47–55.

55.   Kiriukhin M, Tyurin M. Mevalonate production by engineered acetogen biocatalyst
during continuous fermentation of syngas or CO_2/H_2 blend. Bioprocess Biosyst Eng.
2014 Feb;37(2):245–60.

56.   Araki K, Araki M, Yamamura K. Negative Selection with the Diphtheria toxin A fragment
591   Gene Improves Frequency of Cre-Mediated Cassette Exchange in ES Cells. J Biochem
592   (Tokyo). 2006 Dec 1;140(6):793–8.
593   57.   Tyurin M, Kiriukhin M. Selective methanol or formate production during continuous CO2
594   fermentation by the acetogen biocatalysts engineered via integration of synthetic
595   pathways using Tn7-tool. World J Microbiol Biotechnol. 2013 Sep 1;29(9):1611–23.
596   58.   Berzin V, Tyurin M, Kiriukhin M. Selective n-butanol production by Clostridium sp.
597   MTButOH1365 during continuous synthesis gas fermentation due to expression of
598   synthetic thiolase, 3-hydroxy butyryl-CoA dehydrogenase, crotonase, butyryl-CoA
599   dehydrogenase, butyraldehyde dehydrogenase, and NAD-dependent butanol
600   dehydrogenase. Appl Biochem Biotechnol. 2013 Feb;169(3):950–9.
601   59.   Tyurin M, Kiriukhin M. Synthetic 2,3-butanediol pathway integrated using Tn7-tool and
602   powered via elimination of sporulation and acetate production in acetogen biocatalyst.
603   Appl Biochem Biotechnol. 2013 Jul;170(6):1503–24.
604   60.   Razin S, Yogev D, Naot Y. Molecular Biology and Pathogenicity of Mycoplasmas.
605   Microbiol Mol Biol Rev. 1998 Dec;62(4):1094–156.
606   61.   Breton M, Duret S, Béven L, Dubrana M-P, Renaudin J. I-SceI-mediated plasmid
607   deletion and intra-molecular recombination in Spiroplasma citri. J Microbiol Methods.
608   2011 Feb;84(2):216–22.
609   62.   Ayora S, Carrasco B, Cárdenas PP, César CE, Cañas C, Yadav T, et al. Double-strand
610   break repair in bacteria: a view from Bacillus subtilis. FEMS Microbiol Rev. 2011 Nov
611   1;35(6):1055–81.
612   63.   Burgos R, Totten PA. Characterization of the operon encoding the Holliday junction
613   helicase RuvAB from Mycoplasma genitalium and its role in mgpB and mgpC gene variation.
614   J Bacteriol. 2014 Apr;196(8):1608–18.

616